Clinical trial results:
Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients: CABOMAYOR study

Summary

EudraCT number	2019-001639-30
Trial protocol	ES
Global end of trial date	21 November 2023

Results information

Result version number	v1 (current)
This version publication date	20 November 2024
First version publication date	20 November 2024

Trial information

Trial identification

Sponsor protocol code	CABOMAYOR

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04134390
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Spanish Oncology Genitourinary Group – SOGUG
Sponsor organisation address	Velázquez, 7, 3rd floor, Madrid, Spain, 28001
Public contact	Isabel Benítez García-Mauricio, Spanish Oncology Genitourinary Group - SOGUG, 0034 671 42 23 25, projectmanager@sogug.es
Scientific contact	Isabel Grau Miró, Spanish Oncology Genitourinary Group - SOGUG, 0034 610 28 69 15, trialmanager@sogug.es

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 August 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	21 November 2023
Global end of trial reached?	Yes
Global end of trial date	21 November 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Cabozantinib efficacy (Objective Response Rate (ORR) as evaluated by RECIST 1.1 criteria) in previously untreated aged population with metastatic renal cell carcinoma (mRCC).

Protection of trial subjects:

Informed consent has to be obtained prior to initiation of any clinical screening procedure that is performed solely for the purpose of determining eligibility for research; however, evaluations performed as part of routine care prior to informed consent could be utilized as screening evaluations if they fall within the 28-day screening window. Physical examination, hematology, biochemistry, ECG, vital signs, and evaluation of the tumor were made before the inclusion of the patient in the study and during the study treatment.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 November 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 24
Worldwide total number of subjects	24
EEA total number of subjects	24

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	21

85 years and over	3

Subject disposition

Recruitment

Recruitment details:

Of the 38 patients that signed the informed consent, 14 were screening failures and 24 patients have been analysed. All patients included in the analysis received study treatment.

Pre-assignment

Screening details:

All patients that met selection critera and signed the informed consent form were included in the study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Experimental

Arm description:

Cabozantinib 40 mg p.o. once daily.

Arm type	Experimental
Investigational medicinal product name	Cabozantinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Cabozantinib was administered as an oral single 40 mg dose once daily in 28-day cycles. After a period of 4 weeks and if 40 mg is considered tolerated, dose could be escalated to 60 mg to avoid suboptimal exposure to the drug. If this dose was not tolerated, it was de-escalated to 40 mg again. If the dose of 40 mg was not tolerated, a de-escalation to 20 mg, temporary interruption, or stopping cabozantinib were possible.

Number of subjects in period 1	Experimental
Started	24
Completed	24

Baseline characteristics

Reporting groups	
Reporting group title	Overall Study (overall period)

Reporting group description: -

Reporting group values	Overall Study (overall period)	Total	
Number of subjects	24	24	
Age categorical Units: Subjects			
From 65-84 years	21	21	
85 years and over	3	3	
Age continuous Units: years			
median	78.6		
standard deviation	± 4.4	-	
Gender categorical Units: Subjects			
Female	9	9	
Male	15	15	
Race Units: Subjects			
Caucasian	24	24	
ECOG-PS Units: Subjects			
ECOG-PS 0	16	16	
ECOG-PS 1	8	8	
Prior surgery Units: Subjects			
Yes	16	16	
No	8	8	
Prior radiotherapy Units: Subjects			
Yes	7	7	
No	17	17	
Prior chemotherapy Units: Subjects			
Yes	1	1	
No	23	23	
Pulmonary metastasis Units: Subjects			
Yes	16	16	
No	8	8	
Number of locations Units: Subjects			
1 location	7	7	
2 locations	10	10	
3 locations	5	5	

4 locations	2	2	
Number of patients with treatment interruption Units: Subjects			
Yes	17	17	
No	7	7	
Number of patients with dose modification Units: Subjects			
Yes	14	14	
No	10	10	
IMDC classification Units: Subjects			
Favorable risk	8	8	
Intermediate risk	10	10	
Poor risk	2	2	
Not available	4	4	
Relative Cabozantinib dose intensity Units: Percentage			
arithmetic mean	78		
standard deviation	± 22	-	
Treatment time in months Units: Months			
arithmetic mean	11.9		
standard deviation	± 11.5	-	

Subject analysis sets

Subject analysis set title	Overall
Subject analysis set type	Full analysis

Subject analysis set description:
Received study medication

Reporting group values	Overall		
Number of subjects	24		
Age categorical Units: Subjects			
From 65-84 years	21		
85 years and over	3		
Age continuous Units: years			
median	78.6		
standard deviation	± 4.4		
Gender categorical Units: Subjects			
Female	9		
Male	15		
Race Units: Subjects			
Caucasian	24		
ECOG-PS Units: Subjects			

ECOG-PS 0	16		
ECOG-PS 1	8		
Prior surgery Units: Subjects			
Yes	16		
No	8		
Prior radiotherapy Units: Subjects			
Yes	7		
No	17		
Prior chemotherapy Units: Subjects			
Yes	1		
No	23		
Pulmonary metastasis Units: Subjects			
Yes	16		
No	8		
Number of locations Units: Subjects			
1 location	7		
2 locations	10		
3 locations	5		
4 locations	2		
Number of patients with treatment interruption Units: Subjects			
Yes	17		
No	7		
Number of patients with dose modification Units: Subjects			
Yes	14		
No	10		
IMDC classification Units: Subjects			
Favorable risk	8		
Intermediate risk	10		
Poor risk	2		
Not available	4		
Relative Cabozantinib dose intensity Units: Percentage			
arithmetic mean	78		
standard deviation	± 22		
Treatment time in months Units: Months			
arithmetic mean	11.9		
standard deviation	± 11.5		

End points

End points reporting groups

Reporting group title	Experimental
Reporting group description: Cabozantinib 40 mg p.o. once daily.	
Subject analysis set title	Overall
Subject analysis set type	Full analysis
Subject analysis set description: Received study medication	

Primary: Objective response rate

End point title	Objective response rate[1]
End point description: Complete Response (CR) + Partial Response (PR) evaluated by RECIST 1.1 criteria according to investigator criteria.	
End point type	Primary
End point timeframe: Every three months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only one arm. No statistical analysis performed.

End point values	Experimental	Overall		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	24	24		
Units: Patients				
Yes	7	7		
No	17	17		

Statistical analyses

No statistical analyses for this end point

Secondary: Clinical benefit rate

End point title	Clinical benefit rate
End point description: Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) evaluated by RECIST 1.1 criteria according to investigator criteria.	
End point type	Secondary
End point timeframe: Every three months	

End point values	Experimental	Overall		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	24	24		
Units: Patients				
Yes	18	18		
No	6	6		

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-free survival

End point title	Progression-free survival

End point description:

PFS is defined as the time in months since the patient’s study enrolment until patient progression according to RECIST 1.1 criteria.

End point type	Secondary

End point timeframe:

Every three months

End point values	Experimental	Overall		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	24	24		
Units: month				
median (confidence interval 95%)	2.8 (2.0 to 3.6)	2.8 (2.0 to 3.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival

End point title	Overall survival

End point description:

OS is defined as the time in months since the patient’s study enrolment until death.

End point type	Secondary

End point timeframe:

Every three months

End point values	Experimental	Overall		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	24	24		
Units: month				
median (confidence interval 95%)	33.7 (20.5 to 46.8)	33.7 (20.5 to 46.8)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
During study treatment.	
Adverse event reporting additional description:	
No additional description.	
Assessment type	Non-systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	27.0

Reporting groups	
Reporting group title	Overall
Reporting group description: -	

Serious adverse events	Overall		
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 24 (45.83%)		
number of deaths (all causes)	12		
number of deaths resulting from adverse events	4		
Injury, poisoning and procedural complications			
Expired product administered			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Head injury			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Medication error			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Cardiac failure			

subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Nervous system disorders			
Parkinsonism			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ischaemic stroke			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Brain stem haemorrhage			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
General disorders and administration site conditions			
General physical health deterioration			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Gastrointestinal disorders			
Colitis ischaemic			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			

subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Oliguria			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
COVID-19 pneumonia			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Klebsiella bacteraemia			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Overall		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	24 / 24 (100.00%)		
Vascular disorders			
Intermittent claudication			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Hypertension			
subjects affected / exposed	5 / 24 (20.83%)		
occurrences (all)	14		

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	14 / 24 (58.33%)		
occurrences (all)	26		
Oedema			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Oedema peripheral			
subjects affected / exposed	4 / 24 (16.67%)		
occurrences (all)	5		
Mucosal inflammation			
subjects affected / exposed	8 / 24 (33.33%)		
occurrences (all)	10		
Discomfort			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Social circumstances			
Loss of personal independence in daily activities			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Respiratory, thoracic and mediastinal disorders			
Aphonia			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Dysphonia			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Cough			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	3		
Investigations			
Creatine urine decreased			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	4		
Amylase increased			

subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 24 (12.50%)		
occurrences (all)	8		
Blood creatine increased			
subjects affected / exposed	4 / 24 (16.67%)		
occurrences (all)	9		
Blood phosphorus decreased			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Gamma-glutamyltransferase increased			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	4		
Blood glucose increased			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	9		
Weight decreased			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Urine protein/creatinine ratio increased			
subjects affected / exposed	3 / 24 (12.50%)		
occurrences (all)	8		
Glomerular filtration rate decreased			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	4		
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Dysgeusia			
subjects affected / exposed	8 / 24 (33.33%)		
occurrences (all)	8		
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	6 / 24 (25.00%)		
occurrences (all)	17		
Thrombocytopenia			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	5		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	13 / 24 (54.17%)		
occurrences (all)	24		
Dyspepsia			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Abdominal pain			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Abdominal pain upper			
subjects affected / exposed	3 / 24 (12.50%)		
occurrences (all)	3		
Abdominal discomfort			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Nausea			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Vomiting			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	3		
Skin and subcutaneous tissue disorders			
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	5 / 24 (20.83%)		
occurrences (all)	5		
Skin toxicity			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Renal and urinary disorders			

Renal failure subjects affected / exposed occurrences (all) Proteinuria subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 2 3 / 24 (12.50%) 5		
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	5 / 24 (20.83%) 5		
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all) Pain in extremity subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 4 2 / 24 (8.33%) 2		
Infections and infestations COVID-19 subjects affected / exposed occurrences (all) Respiratory tract infection subjects affected / exposed occurrences (all) Urinary tract infection subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 2 2 / 24 (8.33%) 2 4 / 24 (16.67%) 5		
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all) Gout subjects affected / exposed occurrences (all) Hypercholesterolaemia	8 / 24 (33.33%) 12 2 / 24 (8.33%) 2		

subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	4		
Hypertriglyceridaemia			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Hypocalcaemia			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	4		
Hypophosphataemia			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Hypomagnesaemia			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The number of patients recruited was lower than expected, so the results should be interpreted with caution.

Notes: